398 results on '"DeMattos, Ronald"'
Search Results
2. Amyloid-β (Aβ) immunotherapy induced microhemorrhages are associated with activated perivascular macrophages and peripheral monocyte recruitment in Alzheimer’s disease mice
3. Amyloid‐β immunotherapy induced microhemorrhages are associated with activated perivascular macrophages and peripheral monocyte recruitment in Alzheimer’s Disease mice
4. Central pharmacodynamic activity of solanezumab in mild Alzheimer's disease dementia
5. Clusterin Promotes Amyloid Plaque Formation and is Critical for Neuritic Toxicity in a Mouse Model of Alzheimer's Disease
6. Brain to Plasma Amyloid-β Efflux: A Measure of Brain Amyloid Burden in a Mouse Model of Alzheimer's Disease
7. Scavenger Receptor Class B, Type I (SR-BI) is the Major Route for the Delivery of High Density Lipoprotein Cholesterol to the Steroidogenic Pathway in Cultured Mouse Adrenocortical Cells
8. Supplementary Data from Melanoma-Secreted Amyloid Beta Suppresses Neuroinflammation and Promotes Brain Metastasis
9. Supplementary Table from Melanoma-Secreted Amyloid Beta Suppresses Neuroinflammation and Promotes Brain Metastasis
10. Supplementary Figure from Melanoma-Secreted Amyloid Beta Suppresses Neuroinflammation and Promotes Brain Metastasis
11. Data from Melanoma-Secreted Amyloid Beta Suppresses Neuroinflammation and Promotes Brain Metastasis
12. Genome-wide RNAseq study of the molecular mechanisms underlying microglia activation in response to pathological tau perturbation in the rTg4510 tau transgenic animal model
13. Trial of Solanezumab for Mild Dementia Due to Alzheimerʼs Disease
14. Abstract LB052: Melanoma-secreted amyloid beta suppresses neuroinflammation and promotes brain metastasis
15. Low-density lipoprotein receptor overexpression enhances the rate of brain-to-blood Aβ clearance in a mouse model of β-amyloidosis
16. Safety and biomarker effects of solanezumab in patients with Alzheimer’s disease
17. Melanoma-Secreted Amyloid Beta Suppresses Neuroinflammation and Promotes Brain Metastasis
18. New pathways in drug discovery for alzheimer’s disease
19. Apolipoprotein E dose-dependent modulation of β-amyloid deposition in a transgenic mouse model of Alzheimer’s disease
20. Clusterin contributes to caspase-3-independent brain injury following neonatal hypoxia-ischemia
21. Advancing combination therapy for Alzheimer's disease
22. Role of biochemical Alzheimer‘s disease biomarkers as end points in clinical trials
23. Production and characterization of astrocyte-derived human apolipoprotein E isoforms from immortalized astrocytes and their interactions with amyloid-β
24. Liver X Receptor-Mediated Gene Regulation and Cholesterol Homeostasis in Brain: Relevance to Alzheimerʼs Disease Therapeutics
25. In situ AFM studies of astrocyte-secreted apolipoprotein E- and J-containing lipoproteins
26. A liver X receptor and retinoid X receptor heterodimer mediates apolipoprotein E expression, secretion and cholesterol homeostasis in astrocytes
27. Anti-Aβ antibody target engagement: commentary regarding Watt et al. Acta Neuropathol 127:803–810 (2014)
28. Plaque-associated disruption of CSF and plasma amyloid-β (Aβ) equilibrium in a mouse model of Alzheimer's disease
29. Evidence for peripheral clearance of cerebral Aβ protein following chronic, active Aβ immunization in PSAPP mice
30. Additional file 4: of Genome-wide RNAseq study of the molecular mechanisms underlying microglia activation in response to pathological tau perturbation in the rTg4510 tau transgenic animal model
31. Additional file 5: of Genome-wide RNAseq study of the molecular mechanisms underlying microglia activation in response to pathological tau perturbation in the rTg4510 tau transgenic animal model
32. Melanoma-secreted Amyloid Beta Suppresses Neuroinflammation and Promotes Brain Metastasis
33. Pharmacokinetics and Pharmacodynamics of LY2599666, a PEG-Linked Antigen Binding Fragment that Targets Soluble Monomer Amyloid-β
34. Aβ immunization and anti-Aβ antibodies: potential therapies for the prevention and treatment of Alzheimer’s disease
35. Purification and characterization of astrocyte-secreted apolipoprotein E and J-containing lipoproteins from wild-type and human apoE transgenic mice
36. O1‐09‐01: SIGNIFICANT AND SUSTAINED FLORBETAPIR F18 UPTAKE REDUCTION IN PATIENTS WITH SYMPTOMATIC ALZHEIMER'S DISEASE WITH LY3002813, A β‐AMYLOID PLAQUE‐SPECIFIC ANTIBODY
37. P1‐114: MEASUREMENT OF ENDOGENOUS MOUSE TAU IN CEREBROSPINAL FLUID FROM AGED PDAPP MICE FOLLOWING TREATMENT WITH AB‐LOWERING COMPOUNDS
38. [P1-049]: SOLANEZUMAB CENTRAL TARGET ENGAGEMENT AND PHARMACODYNAMIC ACTIVITY IN THE EXPEDITION 3 TRIAL OF PATIENTS WITH MILD AD: COMPARISON TO EXPEDITION/EXPEDITION 2
39. [O2–14–04]: AGGREGATE‐SELECTIVE ANTI‐TAU ANTIBODY MC‐1 DEMONSTRATED ROBUST IN VITRO AND IN VIVO ACTIVITY TO NEUTRALIZE TRANSMISSIBLE TAU AND REDUCE TAU PATHOLOGY
40. [P2-049]: A COMPETITIVE EX-VIVO SCREENING ASSAY TO DETERMINE ABETA ANTIBODY MEDIATED PHAGOCYTOSIS AND PLAQUE SPECIFICITY
41. Peripheral anti-A[Beta] antibody alters CNS and plasma A[Beta] clearance and decreases brain A[Beta] burden in a mouse model of Alzheimer's disease
42. P3-067: Development of a Highly Sensitive TAU Immunoassay to Measure Endogenous Murine TAU in Mouse Cerebrospinal Fluid
43. P4-401: Combination Therapy with a Plaque-Specific Abeta Antibody And A Bace Inhibitor Results in Dramatic Plaque Reduction in a Dose-Dependent Manner in Aged Pdapp Transgenic Mice
44. P1-081: Optimization of the Pharmacokinetic (PK) and Pharmacodynamic (PD) Properties of an Anti-Abeta Antibody M266 FAB Fragment Variant by Site-Specific Pegylation
45. O2-07-02: Trem2-Mediated Early Response by Resident Microglia Limits Diffusion and Toxicity of Amyloid Plaques
46. TREM2-mediated early microglial response limits diffusion and toxicity of amyloid plaques
47. Challenges, solutions, and recommendations for Alzheimer's disease combination therapy
48. TRAILBLAZER-ALZ (NCT03367403): A PHASE 2 DISEASE-MODIFICATION COMBINATION THERAPY TRIAL TARGETING MULTIPLE MECHANISMS OF ACTION ALONG THE AMYLOID PATHWAY
49. SIGNIFICANT AND SUSTAINED FLORBETAPIR F18 UPTAKE REDUCTION IN PATIENTS WITH SYMPTOMATIC ALZHEIMER’S DISEASE WITH LY3002813, A β-AMYLOID PLAQUE-SPECIFIC ANTIBODY
50. MEASUREMENT OF ENDOGENOUS MOUSE TAU IN CEREBROSPINAL FLUID FROM AGED PDAPP MICE FOLLOWING TREATMENT WITH AB-LOWERING COMPOUNDS
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.